Fast-Track Your mRNA-Based Therapeutics & Vaccines from Discovery to Commercialization by Ensuring Targeted Delivery, Durability & Tolerable Immunogenicity Across All Disease Indications As mRNA developments continue to dominate industry news, ranging from winning the Nobel Prize to new clinical candidates, positive Phase I readouts and approvals, the industry is set to reunite in Boston this […]

The 5th Gamma Delta T Cell Therapies Summit will bring together experts from big pharma, biotech and academia to delve into the details of gamma delta biology and its various subsets to offer the audience a well-rounded overview of the landscape currently and the steps needed for it to move forward. Find out more here: […]

There has been many exciting investments and advancements in the field, such as Atavistik Bio raising an additional $40 million to advance their small molecule therapeutics and Servier and Base4 expanding their partnership to accelerate development of neuroscience drugs. However, the discovery of potent RNA targeting small molecules is plagued by limited robust assays and […]

Optimize Safety & De-Risk Efficacy of Viral Vector-Based Gene Therapies The success of gene therapy hinges on overcoming the immunogenicity challenges of viral vectors. With more viral vector-based gene therapies progressing through the pipeline, we need to seek solutions to this critical bottleneck ‘here and now’. The 5th Gene Therapy Immunogenicity Summit is returning to Boston this […]

With Eli Lilly's acquisition of Mablink and Novartis' investment in Tagworks, both centering on their innovative linker and conjugation technologies - optimizing linker chemistry and diversifying conjugation technologies to increase stability and selectivity are becoming increasingly more attractive to ADC developers as they strive for a competitive edge over their peers. As part of the World ADC Series, the 2nd ADC Linker […]

Delivering on the Promise of Precision Medicine with Digital Measures in Neurology Harnessing More Quantitative, Objective & Less Invasive Measures to Reduce Costs & Improve Neurology Patient Experience 2023 welcomed SV95C as the first ever digital endpoint qualified by a regulatory agency, which means that the floodgates have now opened to the potential of digital biomarkers to […]

Exclusively dedicated to uniting AD, QC, and CMC leaders the 3rd Oligonucleotide CMC & Analytical Development Summit is the only industry-led meeting solving your impurity, regulatory, and cost-efficiency challenges in this rapidly evolving field. Across the three days, you'll get the chance to hear from KOLs like Ionis Pharmaceuticals, AstraZeneca, and CAMP4 Therapeutics as the […]